ORPHA:220402
Limited cutaneous systemic sclerosis
Also known as: Limited cutaneous systemic scleroderma
Publications
1,668
Trials
10
Interventional, condition-specific
Researchers
1,240
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Limited cutaneous systemic sclerosis (lcSSc) is a subtype of systemic sclerosis (SSc) characterized by the association of Raynaud's phenomenon with skin fibrosis limited to the hands, face, feet and forearms.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016358
- MeSH:D045745
- UMLS:C0748540
Additional Mondo synonyms (2)
limited cutaneous systemic scleroderma · limited scleroderma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,668 matched papers (1,028 in last 10 years) Source
- Phenotype characterisedPresent
15 HPO annotations (e.g. Narrow foramen obturatorium; Pulmonary arterial hypertension; Abnormality of the skin) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
10 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
15
Associated phenotypes · MONDO:0016358
- Narrow foramen obturatorium
- Pulmonary arterial hypertension
- Abnormality of the skin
- Abnormal skin pigmentation
- Hypopigmented skin patches
Showing 5 of 15 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
2
Drugs / clinical candidates · MONDO_0016358
- NINTEDANIB·phase 3
- MYCOPHENOLATE MOFETIL·phase 2
CTD chemicals (MyDisease.info)
2 associated chemicals. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Fluorouracil · marker/mechanism
- Pentazocine · marker/mechanism
Literature
Is anyone studying this?
1,668
1,668 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,668 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,028 in the last 10 years · low confidence
Phrase hits: 1,666 · MeSH hits: 7
Who's working on it?
1,240
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Campochiaro C6 papers · 2026
Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
Papers in Europe PMC - 02Denton CP6 papers · 2026
Center for Rheumatology, Royal Free London NHS Foundation Trust Hospital.
Papers in Europe PMC - 03
- 04Khanna D5 papers · 2025
Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA.
Papers in Europe PMC - 05Smith V5 papers · 2025
Department of Internal Medicine and Department of Rheumatology Ghent University Hospital Ghent Belgium.
Papers in Europe PMC - 06Brodmann M4 papers · 2026
Division of Angiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Papers in Europe PMC - 07Hafner F4 papers · 2026
Division of Angiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Papers in Europe PMC - 08Jud P4 papers · 2026
Division of Angiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Papers in Europe PMC - 09Liu X4 papers · 2026
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: drlxh@foxmail.com.
Papers in Europe PMC - 10Matucci-Cerinic M4 papers · 2026
Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
10
interventional trials for this specific condition
10 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 409 trials are registered for systemic sclerosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
10 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92.5th percentile).
low confidence · 92.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
10 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07015060·NOT YET RECRUITING·Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis
Not reviewed·Conditions: Scleroderma (Limited and Diffuse)·Matched via MeSH
- NCT07292961·RECRUITING·Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma
Not reviewed·Conditions: Scleroderma · Scleroderma, Localized · Scleroderma Systemic · Scleroderma (Limited and Diffuse)·Matched via MeSH
- NCT06684132·NOT YET RECRUITING·Respiratory Muscle Training in Scleroderma
Not reviewed·Conditions: Scleroderma (Limited and Diffuse)·Matched via MeSH
Broader category: systemic sclerosis
409
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07535931·NOT YET RECRUITING·Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Systemic Sclerosis
Not reviewed·Conditions: Systemic Sclerosis (SSc)·Matched via name phrase
- NCT06675344·RECRUITING·The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
Not reviewed·Conditions: Systemic Sclerosis (SSc)·Matched via name phrase
- NCT03844061·RECRUITING·Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Not reviewed·Conditions: Systemic Sclerosis·Matched via name phrase
- NCT04789850·RECRUITING·Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis
Not reviewed·Conditions: Systemic Sclerosis·Matched via name phrase
- NCT06982534·NOT YET RECRUITING·Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.
Not reviewed·Conditions: Systemic Sclerosis (SSc)·Matched via name phrase
- NCT05989763·RECRUITING·Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
Not reviewed·Conditions: Systemic Sclerosis · Constipation · Gastrointestinal Motility Disorder · Autonomic Dysfunction·Matched via name phrase
- NCT07038447·ENROLLING BY INVITATION·A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Not reviewed·Conditions: Systemic Lupus Erythematosus · Lupus Nephritis · Systemic Sclerosis · Idiopathic Inflammatory Myopathy·Matched via name phrase
- NCT03582800·RECRUITING·Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study
Not reviewed·Conditions: Systemic Sclerosis · Dermatomyositis · iPPSD2·Matched via name phrase
- NCT06859567·NOT YET RECRUITING·Chester Step Test: is It Effective in Scleroderma Patients?
Not reviewed·Conditions: Systemic Sclerosis (SSc) · Chester Step Test · 6 Minutes Walk Test·Matched via name phrase
- NCT07315087·RECRUITING·CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Not reviewed·Conditions: SLE - Systemic Lupus Erythematosus · SSc-Systemic Sclerosis · IIM- Idiopathic Inflammatory Myopathies · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06297096·RECRUITING·Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Not reviewed·Conditions: Systemic Sclerosis · Interstitial Lung Disease·Matched via name phrase
- NCT07184450·RECRUITING·Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Not reviewed·Conditions: Juvenile Dermatomyositis (JDM) · Polyarticular Juvenile Idiopathic Arthritis · Systemic Sclerosis (SSc) · Primary Sjogren's Syndrome·Matched via name phrase
- NCT06954597·RECRUITING·Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis
Not reviewed·Conditions: Digital Ulcers in Systemic Sclerosis·Matched via name phrase
- NCT06980597·RECRUITING·A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Not reviewed·Conditions: Systemic Lupus Erythematosus (SLE) · Idiopathic Inflammatory Myopathy (IIM) · Systemic Sclerosis (SSc) · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT03630211·RECRUITING·Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Not reviewed·Conditions: Systemic Sclerosis · Diffuse Sclerosis Systemic · Interstitial Lung Disease · Pulmonary Hypertension·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07182968·RECRUITING·Cultural Adaptation, Validity, and Reliability of the Turkish Version of The PASTUL Questionnaire
Not reviewed·Conditions: Systemic Sclerosis (SSc) · Systemic Sclerosis (Scleroderma) · Scleroderma (Limited and Diffuse) · Patient Perspective·Matched via MeSH
- NCT07182981·RECRUITING·Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance
Not reviewed·Conditions: Systemic Sclerosis (SSc) · Scleroderma · Scleroderma (Limited and Diffuse) · Scleroderma, Localized·Matched via MeSH
- NCT07183072·RECRUITING·Patients Diagnosed With Scleroderma: Physical Performance and Functionality
Not reviewed·Conditions: Systemic Sclerosis (SSc) · Scleroderma · Scleroderma (Limited and Diffuse) · Scleroderma, Localized·Matched via MeSH
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 31 · after dedupe 31 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 31 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (31)
- isrctn·ISRCTN17000942·Recruiting·The international ‘100 DU’ study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45965456·Suspended·Randomised, open-label international trial with Verapamil alone compared with Verapamil plus another immunotherapy for people with newly diagnosed type 1 diabetes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17285423·No longer recruiting·A study to assess the safety, drug levels in blood and markers of immune system response in patients after multiple doses of a new compound developed for the treatment of cutaneous leishmaniasis, CpG-ODN-D35
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14595136·No longer recruiting·A study of encorafenib and binimetinib given before and after surgery, compared with standard treatment after surgery, in patients with BRAF-mutant melanoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15458851·No longer recruiting·A study to assess safety, drug levels in blood and markers of immune system response after an escalating single dose of a new compound developed for the treatment of cutaneous leishmaniasis, CpG-ODN-D35, in healthy male subjects
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18986715·No longer recruiting·Effects of ultraviolet A1 (UVA1) phototherapy in patients with systemic sclerosis (SSc)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57984704·No longer recruiting·Prevention of vascular damage in scleroderma with angiotensin-converting enzyme inhibition
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN61697120·No longer recruiting·GuARD - GR1014 cutaneous gel Against Radiation Dermatitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN52833273·No longer recruiting·Outcomes of Periodontal Therapy in Rheumatoid Arthritis (OPERA)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11269259·No longer recruiting·A 2-part study to investigate the safety, tolerability and effect of MB272 in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11298659·Recruiting·A clinical study of a new dressing (GellanAA) for the treatment of burn wounds
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15170461·Stopped·A first in human subjects clinical trial of a bioactive dressing designed to reduce scarring of skin burns
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98465849·No longer recruiting·Assessing the safety and effectiveness of the BariClip device in the treatment of severe obesity in Jordan
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN23256704·No longer recruiting·A trial to understand how immune function affects symptoms of psychosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN60385283·No longer recruiting·A study to investigate the safety, tolerability, and potential effect of RXC007 in patients with idiopathic pulmonary fibrosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN57502371·No longer recruiting·A Phase I clinical trial to determine the safety of gemcitabine and nab-paclitaxel administered in combination with ATRA in patients with locally advanced or metastatic pancreatic cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11503604·Recruiting·A Phase II clinical trial to compare the effectiveness of gemcitabine and nab-paclitaxel administered in combination with ATRA vs without ATRA in patients with locally advanced treatment-naïve pancreatic cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10142971·Recruiting·A trial to find a safe dose of drug treatment combined with radiotherapy for non small cell lung cancer (CONCORDE)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17793055·No longer recruiting·A study of the benefit of fat transfer to the peri-oral area for scleroderma patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16942542·No longer recruiting·IL-6 inhibition in patients with depression and low-grade inflammation: the Insight study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN70800019·No longer recruiting·Effects on tocilizumab drug therapy on fat tissue proteins in rheumatoid arthritis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN63206606·Stopped·Clopidogrel in systemic sclerosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10403616·No longer recruiting·Isolation of circulating tumor cells from the blood of prostate cancer patients using an antibody-coated nanodetector
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12127589·No longer recruiting·Validation study of the immunomodulatory effects of ResistAid™
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62704822·No longer recruiting·3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Limited cutaneous systemic sclerosis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Limited cutaneous systemic sclerosis" OR "Limited cutaneous systemic scleroderma" OR "limited scleroderma"
MeSH descriptor terms unioned into the query: Scleroderma, Limited
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Limited cutaneous systemic sclerosis" OR "Limited cutaneous systemic scleroderma" OR "limited scleroderma" OR "Scleroderma, Limited"
Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 10 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"systemic sclerosis"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1668) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T09:53:09.895Z
